Rexahn Pharmaceuticals, Inc. RNN, a clinical stage pharmaceutical
company commercializing potential best in class oncology and CNS therapeutics,
today announced that it has significantly expanded its intellectual property
(IP) around isoquinolinamine, a class of potent anti-cancer compounds. Rexahn
has been issued a continuation patent US 8,314,123 for US 8,034,829 to cover
more new isoquinolinamine compounds and their pharmaceutical composition and
method for producing an anti-tumor effect.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in